LINFOMAS Y TRASPLANTES
University Hospital of Bern
Berna, SuizaPublicaciones en colaboración con investigadores/as de University Hospital of Bern (5)
2024
-
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT
Bone Marrow Transplantation
-
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
HemaSphere, Vol. 8, Núm. 7
-
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217
2023
-
Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4